Immutep (IMMP) has released an update.
Immutep has partnered with MSD to embark on a Phase III trial evaluating their immunotherapy efti with MSD’s KEYTRUDA and chemotherapy in treating non-small cell lung cancer (NSCLC). The trial aims to enroll around 750 patients and could potentially set a new standard of care for NSCLC patients across all levels of PD-L1 expression. Immutep maintains commercial rights to efti, which has shown strong efficacy and safety in previous studies and could improve outcomes for patients less responsive to existing therapies.
For further insights into IMMP stock, check out TipRanks’ Stock Analysis page.
